WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 584150
CAS#: 65-45-2
Description: Salicylamide is a non-steroidal anti-inflammatory agent with analgesic and antipyretic properties. Its medicinal uses are similar to those of aspirin.
MedKoo Cat#: 584150
Name: Salicylamide
CAS#: 65-45-2
Chemical Formula: C7H7NO2
Exact Mass: 137.0477
Molecular Weight: 137.13
Elemental Analysis: C, 61.31; H, 5.15; N, 10.21; O, 23.33
Synonym: Salicylamide; Acket; Allevin; Benesal; Cymidon; Dropsprin; Eggosalil; Panithal; Salizell; Urtosal
IUPAC/Chemical Name: 2-Hydroxybenzamide
InChi Key: SKZKKFZAGNVIMN-UHFFFAOYSA-N
InChi Code: InChI=1S/C7H7NO2/c8-7(10)5-3-1-2-4-6(5)9/h1-4,9H,(H2,8,10)
SMILES Code: O=C(N)C1=CC=CC=C1O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 137.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Song XQ, Liu PP, Liu YA, Zhou JJ, Wang XL. Two dodecanuclear heterometallic [Zn6Ln6] clusters constructed by a multidentate salicylamide salen-like ligand: synthesis, structure, luminescence and magnetic properties. Dalton Trans. 2016 May 10;45(19):8154-63. doi: 10.1039/c6dt00212a. PubMed PMID: 27092471.
2: Przybyłek M, Ziółkowska D, Mroczyńska K, Cysewski P. Propensity of salicylamide and ethenzamide cocrystallization with aromatic carboxylic acids. Eur J Pharm Sci. 2016 Mar 31;85:132-40. doi: 10.1016/j.ejps.2016.02.010. Epub 2016 Feb 17. PubMed PMID: 26898408.
3: Manin AN, Voronin AP, Manin NG, Vener MV, Shishkina AV, Lermontov AS, Perlovich GL. Salicylamide cocrystals: screening, crystal structure, sublimation thermodynamics, dissolution, and solid-state DFT calculations. J Phys Chem B. 2014 Jun 19;118(24):6803-14. doi: 10.1021/jp5032898. Epub 2014 Jun 5. PubMed PMID: 24861612.
4: Dündar Y, Özatik Y, Özatik O, Ergin V, Önkol T, Menevşe A, Erol K, Sahin MF. Synthesis and biological evaluation of the salicylamide and salicylic acid derivatives as anti-estrogen agents. Med Chem. 2012 May;8(3):481-90. PubMed PMID: 22530891.
5: Wein S, Cermak R, Wolffram S, Langguth P. Chronic quercetin feeding decreases plasma concentrations of salicylamide phase II metabolites in pigs following oral administration. Xenobiotica. 2012 May;42(5):477-82. doi: 10.3109/00498254.2011.641607. Epub 2011 Dec 22. PubMed PMID: 22188411.
6: Nilsson J, Shteinman AA, Degerman E, Enyedy EA, Kiss T, Behrens U, Rehder D, Nordlander E. Salicylamide and salicylglycine oxidovanadium complexes with insulin-mimetic properties. J Inorg Biochem. 2011 Dec;105(12):1795-800. doi: 10.1016/j.jinorgbio.2011.09.022. Epub 2011 Sep 22. PubMed PMID: 22056176.
7: Barea C, Pabón A, Castillo D, Zimic M, Quiliano M, Galiano S, Pérez-Silanes S, Monge A, Deharo E, Aldana I. New salicylamide and sulfonamide derivatives of quinoxaline 1,4-di-N-oxide with antileishmanial and antimalarial activities. Bioorg Med Chem Lett. 2011 Aug 1;21(15):4498-502. doi: 10.1016/j.bmcl.2011.05.125. Epub 2011 Jun 12. PubMed PMID: 21724395.
8: Murillo Pulgarín JA, Alañón Molina A, Sánchez-Ferrer Robles I. Simultaneous determination of salicylic acid and salicylamide in biological fluids. Spectrochim Acta A Mol Biomol Spectrosc. 2011 Sep;79(5):909-14. doi: 10.1016/j.saa.2011.03.047. Epub 2011 Apr 8. PubMed PMID: 21561802.
9: Kuziej J, Litinas E, Hoppensteadt DA, Liu D, Walenga JM, Fareed J, Jeske W. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative. Clin Appl Thromb Hemost. 2010 Aug;16(4):377-86. doi: 10.1177/1076029610366439. Epub 2010 May 11. PubMed PMID: 20460347.
10: Pulgarín JA, Molina AA. Direct determination of salicylamide in serum by matrix isopotential synchronous fluorimetry. Talanta. 2002 Mar 4;56(3):557-64. PubMed PMID: 18968528.
11: Dolezal R, Van Damme S, Bultinck P, Waisser K. QSAR analysis of salicylamide isosteres with the use of quantum chemical molecular descriptors. Eur J Med Chem. 2009 Feb;44(2):869-76. doi: 10.1016/j.ejmech.2008.04.020. Epub 2008 May 6. PubMed PMID: 18547684.
12: Ono E, Taniguchi M, Mita H, Akiyama K. Salicylamide-induced anaphylaxis: increased urinary leukotriene E4 and prostaglandin D2 metabolite. Allergy. 2008 Apr;63(4):480-2. doi: 10.1111/j.1398-9995.2007.01616.x. PubMed PMID: 18315738.
13: Yantasee W, Fryxell GE, Lin Y. Voltammetric analysis of europium at screen-printed electrodes modified with salicylamide self-assembled on mesoporous silica. Analyst. 2006 Dec;131(12):1342-6. Epub 2006 Oct 11. PubMed PMID: 17124543.
14: Zarei AR, Afkhami A, Sarlak N. Simultaneous spectrophotometric determination of paracetamol and salicylamide in human serum and pharmaceutical formulations by a differential kinetic method. J AOAC Int. 2005 Nov-Dec;88(6):1695-701. PubMed PMID: 16526453.
15: Zhang L, Zhang JY. Microwave-assisted synthesis of salicylamide via BCl3 mediated coupling. J Comb Chem. 2005 Jul-Aug;7(4):622-6. PubMed PMID: 16004507.
16: Jadrijević-Mladar Takac M, Vikić Topić D, Govorcinović T. FT-IR and NMR spectroscopic studies of salicylic acid derivatives. I. Gentisamide -- a metabolite of salicylamide. Acta Pharm. 2004 Sep;54(3):163-76. PubMed PMID: 15610614.
17: Medić-Sarić M, Mornar A, Jasprica I. Lipophilicity study of salicylamide. Acta Pharm. 2004 Jun;54(2):91-101. PubMed PMID: 15274753.
18: Taira Z, Yabe K, Hamaguchi Y, Hirayama K, Kishimoto M, Ishida S, Ueda Y. Effects of Sho-saiko-to extract and its components, Baicalin, baicalein, glycyrrhizin and glycyrrhetic acid, on pharmacokinetic behavior of salicylamide in carbon tetrachloride intoxicated rats. Food Chem Toxicol. 2004 May;42(5):803-7. PubMed PMID: 15046826.
19: MacDonald CJ, Ciolino HP, Yeh GC. The drug salicylamide is an antagonist of the aryl hydrocarbon receptor that inhibits signal transduction induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res. 2004 Jan 1;64(1):429-34. PubMed PMID: 14729655.
20: Tozuka Y, Oguchi T, Yamamoto K. Adsorption and entrapment of salicylamide molecules into the mesoporous structure of folded sheets mesoporous material (FSM-16). Pharm Res. 2003 Jun;20(6):926-30. PubMed PMID: 12817899.
